{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hematopoietic+Stem+Cell+Therapy&page=2",
    "query": {
      "intervention": "Hematopoietic Stem Cell Therapy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 1437,
    "total_pages": 144,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hematopoietic+Stem+Cell+Therapy&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hematopoietic+Stem+Cell+Therapy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T11:28:51.297Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01177059",
      "title": "Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "OZ1 transduced cells",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Janssen-Cilag Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 68,
      "start_date": "2004-12-06",
      "completion_date": "2017-11-30",
      "has_results": true,
      "last_update_posted_date": "2018-12-12",
      "last_synced_at": "2026-10-07T11:28:51.297Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • San Francisco, California • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01177059"
    },
    {
      "nct_id": "NCT03363945",
      "title": "Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "MDR-101",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medeor Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2018-03-15",
      "completion_date": "2024-04-11",
      "has_results": false,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-10-07T11:28:51.297Z",
      "location_count": 18,
      "location_summary": "Loma Linda, California • Los Angeles, California • Stanford, California + 15 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03363945"
    },
    {
      "nct_id": "NCT05618301",
      "title": "Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Motixafortide",
          "type": "DRUG"
        },
        {
          "name": "Natalizumab",
          "type": "DRUG"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2023-07-07",
      "completion_date": "2025-06-24",
      "has_results": false,
      "last_update_posted_date": "2025-08-11",
      "last_synced_at": "2026-10-07T11:28:51.297Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05618301"
    },
    {
      "nct_id": "NCT05366257",
      "title": "Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diffuse Large B-cell Lymphoma (DLBCL)"
      ],
      "interventions": [
        {
          "name": "CAR-T",
          "type": "OTHER"
        },
        {
          "name": "Allo-HSCT cohort",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 160602,
      "start_date": "2020-08-17",
      "completion_date": "2021-05-10",
      "has_results": false,
      "last_update_posted_date": "2022-07-05",
      "last_synced_at": "2026-10-07T11:28:51.297Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05366257"
    },
    {
      "nct_id": "NCT01336712",
      "title": "Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Leukemia",
        "Acute Leukemia",
        "Hodgkin's Disease",
        "Non-Hodgkin's Lymphoma",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Peripheral Blood Stem Cell Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Northside Hospital, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": "2011-04",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2016-01-14",
      "last_synced_at": "2026-10-07T11:28:51.297Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01336712"
    },
    {
      "nct_id": "NCT05621759",
      "title": "Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft Vs Host Disease"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 27,
      "start_date": "2022-09-07",
      "completion_date": "2027-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-10-07T11:28:51.297Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05621759"
    },
    {
      "nct_id": "NCT04483206",
      "title": "Personalized Autologous Transplant for Multiple Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2021-05-20",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-07T11:28:51.297Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04483206"
    },
    {
      "nct_id": "NCT02999984",
      "title": "Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency Due to ADA Deficiency"
      ],
      "interventions": [
        {
          "name": "Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)",
          "type": "GENETIC"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "PEG-ADA ERT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Days",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "30 Days to 17 Years"
      },
      "enrollment_count": 10,
      "start_date": "2016-12-16",
      "completion_date": "2019-09-26",
      "has_results": true,
      "last_update_posted_date": "2022-08-03",
      "last_synced_at": "2026-10-07T11:28:51.297Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02999984"
    },
    {
      "nct_id": "NCT02566304",
      "title": "Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Myeloid Leukemia in Remission",
        "Aplastic Anemia",
        "Chronic Myelomonocytic Leukemia",
        "Hodgkin Lymphoma",
        "Indolent Non-Hodgkin Lymphoma",
        "Malignant Neoplasm",
        "Myelodysplastic Syndrome",
        "Myeloproliferative Neoplasm",
        "Plasma Cell Myeloma",
        "Refractory Anemia",
        "Refractory Anemia With Excess Blasts",
        "Refractory Anemia With Ring Sideroblasts",
        "Refractory Cytopenia With Multilineage Dysplasia",
        "Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "T Cell-Depleted Donor Lymphocyte Infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2015-11-13",
      "completion_date": "2024-02-13",
      "has_results": true,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-10-07T11:28:51.297Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02566304"
    },
    {
      "nct_id": "NCT00357084",
      "title": "Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 53,
      "start_date": "2006-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-09-14",
      "last_synced_at": "2026-10-07T11:28:51.297Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00357084"
    }
  ]
}